Travatan Z (Travoprost) Patent Expiration, LOE Window & CMS Spending

Travatan Z (Travoprost) by Sandoz: FDA Orange Book LOE 2029-10-13, 0 AB generics, $15.5M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSandoz
FDA Application & PathwayN021994 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-10-13
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$15.5M
2024 Medicare Part D Spend$10.6M
2024 Medicaid Spend$4.9M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 26.8% 2-yr change)